Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcus Biosciences Inc (NY: RCUS )

14.28 -0.45 (-3.05%)
Official Closing Price Updated: 7:00 PM EDT, Jul 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 489,198
Open 14.81
Bid (Size) 14.09 (1)
Ask (Size) 15.21 (1)
Prev. Close 14.73
Today's Range 14.13 - 15.07
52wk Range 12.95 - 25.47
Shares Outstanding 90,900,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Taiho Pharmaceutical Exercises Option for an Exclusive License to Quemliclustat in Japan and Certain Territories in Asia
From Arcus Biosciences
Via Business Wire

Performance

YTD
-27.44%
-27.44%
1 Month
-11.80%
-11.80%
3 Month
-2.12%
-2.12%
6 Month
-6.91%
-6.91%
1 Year
-27.29%
-27.29%

More News

Read More
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciences
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Navigating 5 Analyst Ratings For Arcus Biosciences
Via Benzinga
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Completes Patient Enrollment in Phase 3 Trial Evaluating a Domvanalimab-Containing Regimen in First-Line Metastatic Upper GI Cancers
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Arcus Biosciences
Via Business Wire
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studies
Via Benzinga
Gilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI Cancers
From Gilead Sciences, Inc.
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
From Arcus Biosciences
Via Business Wire
Arcus Biosciences Announces New Employment Inducement Grants
From Arcus Biosciences
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.